Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th Eur...
July 31 2019 - 9:57AM
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company
focused on innovative therapeutics to treat orphan autoimmune and
inflammatory diseases where the complement and/or leukotriene
systems are implicated, today announced an oral presentation will
be given at the 28th EADV Congress. The event is being held in
Madrid, Spain, October 9-13, 2019.
The oral presentation will describe the safety and efficacy data
from Akari’s Phase II clinical trial of nomacopan in adult patients
with mild to moderate bullous pemphigoid. The presenter, Dr.
Christian Sadik, M.D., is principal investigator at one of the
trial sites.
Presentation details
Title: |
A Phase II clinical trial of safety and efficacy of rVA576
(Nomacopan) in adult mild to moderate bullous pemphigoid patients,
first results of the pilot study |
Session date and time: |
Thursday October 10, 2019, 16:00 CEST |
Location: |
IFEMA Feria de Madrid |
Presenter: |
Dr. Christian Sadik, M.D., Department of Dermatology, University of
Lubeck, Germany |
|
|
About Bullous Pemphigoid
Bullous Pemphigoid (BP) is a severe orphan autoimmune
inflammatory skin disease with an estimated prevalence of 18 per
100,000 population in the U.S. and Europe. BP has a relapsing
course over several years and is currently treated primarily with
steroids and immunosuppressants, which bring with them well-known
side effects, especially in the elderly population affected by BP.
In patients with bullous pemphigoid there is evidence that both
terminal complement activation (C5) and the lipid mediator
leukotriene B4 (LTB4) have a central role in driving the
disease.
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing
inhibitors of acute and chronic inflammation, specifically for the
treatment of rare and orphan diseases, in particular those where
the complement (C5) or leukotriene (LTB4) systems, or both
complement and leukotrienes together, play a primary role in
disease progression. Akari's lead drug candidate, nomacopan
(formerly known as Coversin), is a C5 complement inhibitor that
also independently and specifically inhibits leukotriene B4 (LTB4)
activity. Nomacopan is currently being clinically evaluated in four
indications: bullous pemphigoid (BP), atopic keratoconjunctivitis
(AKC), thrombotic microangiopathy (TMA), and paroxysmal nocturnal
hemoglobinuria (PNH). Akari believes that the dual action of
nomacopan on both C5 and LTB4 may be beneficial in AKC and BP.
Akari is also developing other tick derived proteins, including
longer acting versions.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control. Such risks and uncertainties for our company
include, but are not limited to: needs for additional capital to
fund our operations, our ability to continue as a going concern;
uncertainties of cash flows and inability to meet working capital
needs; an inability or delay in obtaining required regulatory
approvals for nomacopan and any other product candidates,
which may result in unexpected cost expenditures; our ability to
obtain orphan drug designation in additional indications; risks
inherent in drug development in general; uncertainties in obtaining
successful clinical results for nomacopan and any other product
candidates and unexpected costs that may result therefrom;
difficulties enrolling patients in our clinical trials; failure to
realize any value of nomacopan and any other product candidates
developed and being developed in light of inherent risks and
difficulties involved in successfully bringing product candidates
to market; inability to develop new product candidates and support
existing product candidates; the approval by the FDA and EMA and
any other similar foreign regulatory authorities of other competing
or superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for nomacopan may not
be as large as expected; risks associated with the departure of our
former Chief Executive Officers and other executive officers; risks
associated with the SEC investigation; inability to obtain,
maintain and enforce patents and other intellectual property rights
or the unexpected costs associated with such enforcement or
litigation; inability to obtain and maintain commercial
manufacturing arrangements with third party manufacturers or
establish commercial scale manufacturing capabilities; the
inability to timely source adequate supply of our active
pharmaceutical ingredients from third party manufacturers on whom
the company depends; unexpected cost increases and pricing
pressures and risks and other risk factors detailed in our public
filings with the U.S. Securities and Exchange Commission, including
our most recently filed Annual Report on Form 20-F filed with the
SEC. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no
obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
For more informationInvestor Contact:
Peter VozzoWestwicke(443) 213-0505peter.vozzo@westwicke.com
Media Contact:
Sukaina Virji / Nicholas Brown / Lizzie SeeleyConsilium
Strategic Communications+44 (0)20 3709
5700Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2024 to May 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From May 2023 to May 2024